BeStock  
Stocks › Biotechnology › CLDX

Celldex Therapeutics CLDX

US equityMarket cap rank #2636Biotechnology
$27.42 −$0.54 (-1.93%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.40 -0.07%
Open$27.01
Prev close$27.96
Day range$26.64 – $28.43
Volume1.72M
Market cap$2.15B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership118.5%+7.25 pts vs. prior quarter
Institutions holding315+6 vs. prior quarter
Insider trades (recent)44 buys / 6 sellsNet buying
Short interest12.65% of floatDays to cover 10.4 · as of 30 Oct 2026
Short-sale volume share25.0%5-day average of daily volume

Short-sale volume as % of daily volume

15%22%30%38%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$5.31M (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

+$4.7MSuper+$559.7KBig−$235.6KMid+$834.7KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 44.7% of shares outstanding.

Largest holders

  • Wellington Management Group12.15%
  • FMR11.00%
  • BlackRock8.85%
  • Kynam Capital Management, LP6.78%
  • T. Rowe Price Group, Inc.5.97%
  • State Street Global Advisors4.43%
  • Vanguard Capital Management, LLC4.43%
  • Deep Track Capital, LP3.74%

By investor type

  • Mutual Fund77.21%
  • Hedge Fund28.66%
  • VC/PE Fund7.52%
  • Public Company3.06%
  • Insurance Company0.92%
  • Private Company0.63%
  • Government Pension Fund0.51%
  • Individual/Insider0.24%

Reported short interest has risen from 9.64% to 12.65% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +4,914,623 11.0%
Federated Hermes, Inc. Mutual Fund 2026/Q3 +556,724 1.3%
Silverarc Capital Management, LLC Hedge Fund 2026/Q3 +487,589 0.6%
UBS Asset Management Mutual Fund 2026/Q3 +447,280 1.4%
Morgan Stanley Public Company 2026/Q3 +398,788 0.8%
Fisher Investments Mutual Fund 2026/Q3 +261,178 1.6%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +383,874 0.7%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +2,599,855 6.0%
Deep Track Capital, LP VC/PE Fund 2026/Q3 +1,655,172 3.7%
Logos Global Management, L.P. Hedge Fund 2026/Q3 +1,650,000 2.7%
BlackRock Mutual Fund 2026/Q3 +1,632,645 8.9%
State Street Global Advisors Mutual Fund 2026/Q3 +1,096,259 5.0%
Driehaus Capital Management LLC Mutual Fund 2026/Q3 +989,442 1.3%
Wellington Management Group Mutual Fund 2026/Q3 +983,195 12.2%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +642,171 1.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
24 Jun 2026 Harry Penner Chairperson Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Herbert Conrad Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 James Marino Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Ronald Pepin Chief Business Officer & Senior VP Other Derivative Acquisition +20,000 $34.09 20,000
24 Jun 2026 Anthony Marucci Chief Executive Officer Other Derivative Acquisition +375,000 $34.09 375,000
24 Jun 2026 Tibor Keler Founder, Chief Scientific Officer & Executive VP Other Derivative Acquisition +115,000 $34.09 115,000
24 Jun 2026 Diane Young Senior VP & Chief Medical Officer Other Derivative Acquisition +57,000 $34.09 57,000
24 Jun 2026 Sarah Cavanaugh Senior Vice President of Corporate Affairs & Administration Other Derivative Acquisition +95,000 $34.09 95,000
24 Jun 2026 Garry Neil Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Keith Brownlie Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Cheryl Cohen Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Elizabeth Crowley Chief Product Development Officer & Senior VP Other Derivative Acquisition +100,000 $34.09 100,000
24 Jun 2026 Rita Jain Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Sam Martin Senior VP, CFO, Secretary & Treasurer Other Derivative Acquisition +93,000 $34.09 93,000
24 Jun 2026 Margo Heath-Chiozzi Senior Vice President of Regulatory Affairs Other Derivative Acquisition +95,000 $34.09 95,000
24 Jun 2026 Denice Torres Independent Director Other Derivative Acquisition +26,000 $34.09 26,000
24 Jun 2026 Freddy Jimenez General Counsel Other Derivative Acquisition +93,000 $34.09 93,000
24 Jun 2026 Teri Lawver SVP & Chief Commercial Officer Other Derivative Acquisition +90,000 $34.09 90,000
1 Jan 2026 Sam Martin Senior VP, CFO, Secretary & Treasurer Derivative Exercise and Retained +4,817 $10.38 32,942
14 Dec 2025 Ronald Pepin Chief Business Officer & Senior VP Derivative Exercise and Retained +19,333 $9.02 20,097

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 9,936,646 12.7% 10.4
15 Oct 2026 9,598,891 12.2% 5.9
30 Sep 2026 11,006,720 14.0% 3.8
15 Sep 2026 8,953,127 11.4% 13.1
31 Aug 2026 8,641,597 11.0% 12.2
14 Aug 2026 7,569,702 9.6% 7.9

Discussion

No comments yet — be the first to weigh in on CLDX.

Sign in to join the discussion.

Scroll to Top